Factors Influencing Collection and Engraftment of CD34+Cells in Patients with Breast Cancer Following High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Cell Transplantation
- 1 February 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy & Stem Cell Research
- Vol. 9 (1) , 103-109
- https://doi.org/10.1089/152581600319685
Abstract
Although autologous PBPC transplantation is being used increasingly for the treatment of breast cancer, there are few data on factors influencing mobilization and engraftment in these patients. We have analyzed these factors in 70 patients with advanced or metastatic breast cancer undergoing autologous PBPC transplantation. All patients were mobilized after stimulation with G-CSF, and a median of 3.16 X 106/kg CD34+ cells (range 0.75-23.33) were infused. All patients received conditioning with a combination of cyclophosphamide, thiotepa, and carboplatin, and postinfusion G-CSF was administered to 60 patients. The median times to reach 0.5 X 109/L and 1 X 109/L neutrophils were 10 and 11 days, respectively. The median times to obtain 20 X 109/L and 50 X 109/L platelets were 12 and 18 days, respectively. An analysis of factors that influence CD34+ cell collection was performed by linear regression. Previous radiation therapy and increasing age were associated with lower numbers of CD34+ cells collected. Those variables that could influence the tempo of engraftment were examined by multivariate analysis using Cox regression models. The number of CD34+ cells infused was found to influence both neutrophil and platelet recovery. The use of G-CSF after transplant, accelerated neutrophil recovery, and having more than six cycles of previous chemotherapy was an unfavorable factor for recovering >50 X 109/L platelets.Keywords
This publication has 27 references indexed in Scilit:
- Factors Influencing Mobilization and Engraftment in Patients with Metastatic Breast Cancer Undergoing PBSC TransplantationJournal of Hematotherapy, 1999
- The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescueBone Marrow Transplantation, 1998
- Blood and marrow transplantation activity in Europe 1996Bone Marrow Transplantation, 1998
- High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodesBone Marrow Transplantation, 1997
- Peripheral Blood Stem Cell TransplantationVox Sanguinis, 1997
- Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftmentBone Marrow Transplantation, 1997
- Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell contentBone Marrow Transplantation, 1997
- Autologous Transplantation of Blood Stern Cells Mobilized with Filgrastim Alone in 93 Patients with Malignancies: The Number of CD34+ Cells Reinfused Is the Only Factor Predicting Both Granulocyte and Platelet RecoveryJournal of Hematotherapy, 1996
- Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantationBritish Journal of Haematology, 1994
- Blood-derived haematopoietic cell transplants: blood to blood?The Lancet, 1991